<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
  <title>GIDS Research Radar · Smallpox</title>
  <link>https://globalinfectiousdisease.com/research/</link>
  <description>Published infectious-disease literature filtered to Smallpox.</description>
  <language>en</language>
  <atom:link href="https://globalinfectiousdisease.com/research/rss/diseases/smallpox.xml" rel="self" type="application/rss+xml" />
  <lastBuildDate>Wed, 09 Sep 2026 07:02:01 GMT</lastBuildDate>
  <item>
    <title>APOBEC3-driven attenuation of the 2022 global outbreak monkeypox virus relative to its clade IIb ancestor</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-1038-s41467-026-76580-7-00f2b79e/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-1038-s41467-026-76580-7-00f2b79e/</guid>
    <pubDate>Tue, 11 Aug 2026 00:00:00 GMT</pubDate>
    <description>The article is relevant to monkeypox outbreak investigation and transmission dynamics because it addresses phenotypic differences in a virus lineage associated with the 2022 global epidemic. Its focus on zoonotic MPXV and orthopoxvirus transmission gives it One Health relevance.</description>
    <category>Monkeypox</category>
    <category>Smallpox</category>
    <category>Outbreak investigation</category>
    <category>Transmission dynamics</category>
    <category>One Health</category>
    <category>Journal article</category>
  </item>
  <item>
    <title>Cross-reactive immunity against orthopoxviruses after monkeypox virus infection or smallpox vaccination</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-1016-j-ijid-2026-109047-cef9afc2/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-1016-j-ijid-2026-109047-cef9afc2/</guid>
    <pubDate>Sat, 01 Aug 2026 00:00:00 GMT</pubDate>
    <description>Monkeypox infection and smallpox vaccination may provide cross-protection against orthopoxviruses. Early IgA detection could support mpox diagnosis in asymptomatic high-risk individuals, and complement-dependent neutralization assays may improve cross-immunity assessment.</description>
    <category>Smallpox</category>
    <category>Monkeypox</category>
    <category>Vaccination</category>
    <category>Vaccine effectiveness</category>
    <category>Journal article</category>
  </item>
  <item>
    <title>Long-term consequences of monkeypox virus infection or modified vaccinia virus Ankara vaccination in Belgium (MPX-COHORT and POQS-FU-PLUS): a 24-month prospective and retrospective cohort study</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-1016-s1473-3099-25-00545-6-9f0c6065/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-1016-s1473-3099-25-00545-6-9f0c6065/</guid>
    <pubDate>Sun, 01 Feb 2026 00:00:00 GMT</pubDate>
    <description>The observed differences in immune durability between natural infection and vaccination highlight potential considerations for maintaining population-level protection against circulating orthopoxviruses.</description>
    <category>Smallpox</category>
    <category>Monkeypox</category>
    <category>Vaccination</category>
    <category>Cohort study</category>
  </item>
  <item>
    <title>Safety and effectiveness of MVA-BN vaccination against mpox in at-risk individuals in Germany (SEMVAc and TEMVAc): a combined prospective and retrospective cohort study</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-1016-s1473-3099-25-00018-0-0c50fdeb/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-1016-s1473-3099-25-00018-0-0c50fdeb/</guid>
    <pubDate>Tue, 01 Jul 2025 00:00:00 GMT</pubDate>
    <description>The article provides Germany-specific observational evidence on MVA-BN safety and estimated effectiveness in the population studied during the 2022-2023 mpox period. Its findings may inform editorial context about vaccination evidence, including the reported difference in estimated effectiveness by HIV status, but they do not establish causality or confirm a current surveillance pattern.</description>
    <category>Smallpox</category>
    <category>Monkeypox</category>
    <category>Vaccination</category>
    <category>Vaccine effectiveness</category>
    <category>Outbreak investigation</category>
    <category>Transmission dynamics</category>
    <category>Cohort study</category>
  </item>
  <item>
    <title>Use of JYNNEOS (Smallpox and Mpox Vaccine, Live, Nonreplicating) for Persons Aged ≥18 Years at Risk for Mpox During an Mpox Outbreak: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-15585-mmwr-mm7422a3-e39ea2c9/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-15585-mmwr-mm7422a3-e39ea2c9/</guid>
    <pubDate>Thu, 19 Jun 2025 00:00:00 GMT</pubDate>
    <description>The recommendations provide outbreak-specific vaccination guidance amid ongoing mpox transmission and substantial morbidity and mortality. Future need for the outbreak recommendation will be reassessed as the outbreak evolves.</description>
    <category>Smallpox</category>
    <category>Monkeypox</category>
    <category>Vaccination</category>
    <category>Outbreak investigation</category>
    <category>Transmission dynamics</category>
    <category>Journal article</category>
  </item>
  <item>
    <title>Mpox in Africa: What we know and what is still lacking</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-1371-journal-pntd-0013148-060ab7b4/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-1371-journal-pntd-0013148-060ab7b4/</guid>
    <pubDate>Thu, 12 Jun 2025 00:00:00 GMT</pubDate>
    <description>The authors argue Mpox has the potential to disrupt health systems and undermine progress toward the 2030 sustainable development goals, calling for financial and human resource support from countries both within and outside Africa.</description>
    <category>Monkeypox</category>
    <category>Smallpox</category>
    <category>Surveillance</category>
    <category>Outbreak investigation</category>
    <category>Transmission dynamics</category>
    <category>Vaccination</category>
    <category>Climate and environment</category>
    <category>One Health</category>
    <category>Journal article</category>
  </item>
  <item>
    <title>Orthopoxvirus-specific antibodies wane to undetectable levels 1 year after MVA-BN vaccination of at-risk individuals, the Netherlands, 2022 to 2023</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-2807-1560-7917-es-2024-29-38-2400575-f7a0beb2/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-2807-1560-7917-es-2024-29-38-2400575-f7a0beb2/</guid>
    <pubDate>Thu, 19 Sep 2024 00:00:00 GMT</pubDate>
    <description>The findings indicate that antibody responses to MVA-BN vaccination may not persist beyond one year, highlighting the need for ongoing surveillance to assess the public health implications of declining antibody levels for mpox outbreak preparedness.</description>
    <category>Smallpox</category>
    <category>Monkeypox</category>
    <category>Vaccination</category>
    <category>Outbreak investigation</category>
    <category>Surveillance</category>
    <category>Journal article</category>
  </item>
  <item>
    <title>Mpox in people with past infection or a complete vaccination course: a global case series</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-1016-s1473-3099-23-00492-9-83571f46/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-1016-s1473-3099-23-00492-9-83571f46/</guid>
    <pubDate>Mon, 01 Jan 2024 00:00:00 GMT</pubDate>
    <description>Cataloging symptom profiles in previously immune populations aids researchers in understanding how prior exposure modifies disease presentation within affected networks.</description>
    <category>Monkeypox</category>
    <category>Smallpox</category>
    <category>Vaccination</category>
    <category>Outbreak investigation</category>
    <category>Journal article</category>
  </item>
  <item>
    <title>Vaccine Effectiveness of JYNNEOS against Mpox Disease in the United States</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-1056-nejmoa2215201-466804dd/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-1056-nejmoa2215201-466804dd/</guid>
    <pubDate>Thu, 29 Jun 2023 00:00:00 GMT</pubDate>
    <description>The findings support the usefulness of JYNNEOS vaccination against mpox disease and suggest greater protection with completion of the two-dose series, relevant to U.S. outbreak control among at-risk adults.</description>
    <category>Monkeypox</category>
    <category>Smallpox</category>
    <category>HIV infection</category>
    <category>AIDS</category>
    <category>Vaccination</category>
    <category>Vaccine effectiveness</category>
    <category>Outbreak investigation</category>
    <category>Case-control study</category>
  </item>
  <item>
    <title>Mpox outbreak in the Netherlands, 2022: public health response, characteristics of the first 1,000 cases and protection of the first-generation smallpox vaccine</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-2807-1560-7917-es-2023-28-12-2200772-971f344b/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-2807-1560-7917-es-2023-28-12-2200772-971f344b/</guid>
    <pubDate>Thu, 23 Mar 2023 00:00:00 GMT</pubDate>
    <description>The findings characterize a high-incidence mpox outbreak in a specific population and provide quantitative estimates of vaccine protection, contributing evidence relevant to vaccination strategy and risk communication for at-risk communities.</description>
    <category>Smallpox</category>
    <category>Monkeypox</category>
    <category>Vaccination</category>
    <category>Travel medicine</category>
    <category>Outbreak investigation</category>
    <category>Transmission dynamics</category>
    <category>Vaccine effectiveness</category>
    <category>Journal article</category>
  </item>
  <item>
    <title>Low levels of monkeypox virus-neutralizing antibodies after MVA-BN vaccination in healthy individuals</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-1038-s41591-022-02090-w-3f5be3bf/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-1038-s41591-022-02090-w-3f5be3bf/</guid>
    <pubDate>Tue, 18 Oct 2022 00:00:00 GMT</pubDate>
    <description>These observations address knowledge gaps surrounding authorized MVA-BN deployment during a recently declared international health emergency by quantifying early immune responses.</description>
    <category>Influenza</category>
    <category>Monkeypox</category>
    <category>Smallpox</category>
    <category>Vaccination</category>
    <category>Outbreak investigation</category>
    <category>Vaccine effectiveness</category>
    <category>Journal article</category>
  </item>
  <item>
    <title>The changing epidemiology of human monkeypox—A potential threat? A systematic review</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-1371-journal-pntd-0010141-156f368b/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-1371-journal-pntd-0010141-156f368b/</guid>
    <pubDate>Fri, 11 Feb 2022 00:00:00 GMT</pubDate>
    <description>The review highlights the global relevance of monkeypox given its spread beyond endemic African settings and suggests that enhanced surveillance is needed to monitor its evolving epidemiology.</description>
    <category>Monkeypox</category>
    <category>Smallpox</category>
    <category>Travel medicine</category>
    <category>Surveillance</category>
    <category>Transmission dynamics</category>
    <category>Vaccination</category>
    <category>One Health</category>
    <category>Systematic review</category>
  </item>
  <item>
    <title>Micro-simulation of a smallpox outbreak using official register data</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-2807-ese-15-35-19651-en-b9605ba4/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-2807-ese-15-35-19651-en-b9605ba4/</guid>
    <pubDate>Thu, 02 Sep 2010 00:00:00 GMT</pubDate>
    <description>The findings provide a model-based comparison of vaccination strategies for controlling a simulated smallpox outbreak and may inform analysis of vaccination policy in comparable modeled settings. The abstract does not establish effectiveness in actual outbreaks or surveillance data.</description>
    <category>COVID-19</category>
    <category>Smallpox</category>
    <category>Influenza</category>
    <category>Vaccination</category>
    <category>Outbreak investigation</category>
    <category>Surveillance</category>
    <category>Transmission dynamics</category>
    <category>Health policy</category>
    <category>Journal article</category>
  </item>
  <item>
    <title>Risks and Benefits of Preexposure and Postexposure Smallpox Vaccination1</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-3201-eid0911-030369-f24a0548/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-3201-eid0911-030369-f24a0548/</guid>
    <pubDate>Sat, 01 Nov 2003 00:00:00 GMT</pubDate>
    <description>The findings provide quantitative decision thresholds for smallpox vaccination policy, balancing rare but serious vaccine complications against bioterrorism or outbreak risk in the post-eradication era.</description>
    <category>Smallpox</category>
    <category>SARS</category>
    <category>COVID-19</category>
    <category>Vaccination</category>
    <category>Transmission dynamics</category>
    <category>Vaccine effectiveness</category>
    <category>Journal article</category>
  </item>
  <item>
    <title>The confirmation and maintenance of smallpox eradication.</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-1056-nejm198011273032204-4b7984fd/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-1056-nejm198011273032204-4b7984fd/</guid>
    <pubDate>Thu, 27 Nov 1980 00:00:00 GMT</pubDate>
    <description>A key post-certification account of how eradication status was confirmed and guarded.</description>
    <category>Smallpox</category>
    <category>Surveillance</category>
    <category>Vaccination</category>
    <category>Health policy</category>
    <category>Journal article</category>
  </item>
</channel>
</rss>
